Continental Investors Services Inc. Invests $1.55 Million in CRISPR Therapeutics AG (NASDAQ:CRSP)

Continental Investors Services Inc. purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 21,440 shares of the company’s stock, valued at approximately $1,554,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Bouvel Investment Partners LLC lifted its holdings in shares of CRISPR Therapeutics by 1.0% during the third quarter. Bouvel Investment Partners LLC now owns 18,726 shares of the company’s stock valued at $1,224,000 after purchasing an additional 190 shares during the last quarter. Cetera Investment Advisers lifted its stake in CRISPR Therapeutics by 3.0% in the 2nd quarter. Cetera Investment Advisers now owns 8,064 shares of the company’s stock worth $490,000 after acquiring an additional 237 shares in the last quarter. E Fund Management Co. Ltd. lifted its stake in CRISPR Therapeutics by 3.6% in the 3rd quarter. E Fund Management Co. Ltd. now owns 7,113 shares of the company’s stock worth $465,000 after acquiring an additional 245 shares in the last quarter. Signaturefd LLC lifted its stake in CRISPR Therapeutics by 14.3% in the 3rd quarter. Signaturefd LLC now owns 2,025 shares of the company’s stock worth $132,000 after acquiring an additional 253 shares in the last quarter. Finally, Kistler Tiffany Companies LLC lifted its stake in CRISPR Therapeutics by 51.6% in the 3rd quarter. Kistler Tiffany Companies LLC now owns 782 shares of the company’s stock worth $51,000 after acquiring an additional 266 shares in the last quarter. Institutional investors own 71.51% of the company’s stock.

CRISPR Therapeutics Stock Up 0.8 %

NASDAQ CRSP opened at $45.74 on Friday. The stock has a fifty day simple moving average of $49.78 and a 200 day simple moving average of $53.79. CRISPR Therapeutics AG has a twelve month low of $38.94 and a twelve month high of $86.95. The company has a market capitalization of $3.60 billion, a price-to-earnings ratio of -5.46 and a beta of 1.73.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last issued its quarterly earnings results on Tuesday, February 21st. The company reported ($1.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.27) by $0.86. CRISPR Therapeutics had a negative return on equity of 31.85% and a negative net margin of 54,271.70%. The firm had revenue of $6.00 million during the quarter, compared to the consensus estimate of $7.37 million. During the same period last year, the business posted ($1.84) EPS. The business’s revenue was down 53.5% compared to the same quarter last year. Research analysts expect that CRISPR Therapeutics AG will post -7.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. EF Hutton Acquisition Co. I restated a “buy” rating and set a $75.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, February 22nd. Chardan Capital decreased their price objective on CRISPR Therapeutics from $153.00 to $123.00 and set a “buy” rating for the company in a research note on Wednesday, February 22nd. Robert W. Baird began coverage on CRISPR Therapeutics in a report on Monday, March 6th. They set a “neutral” rating and a $46.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $70.00 target price on shares of CRISPR Therapeutics in a report on Monday, February 27th. Finally, StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Wednesday, February 22nd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $75.06.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $51.47, for a total transaction of $1,286,750.00. Following the completion of the sale, the chief executive officer now directly owns 369,111 shares in the company, valued at approximately $18,998,143.17. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 75,000 shares of company stock worth $3,516,250. Company insiders own 5.30% of the company’s stock.

About CRISPR Therapeutics

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.